Tafamidis Meglumine Capsule shortage
Tafamidis Meglumine Capsule is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 18, 2026.
Pfizer is stopping production of Vyndaquel (tafamidis meglumine) 20 mg capsules, with sales ending in December 2025. No other manufacturers of this product are listed, so there is currently no reported available source.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Tafamidis Meglumine Capsule. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 29, 2025Currently in shortage1 of 1 product affected.
-
Sep 29, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Pfizer Inc. 📞 800-879-3477 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-8730-30) | — | — | Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025. | — |
These rows are manufacturer reports to the FDA for Tafamidis Meglumine Capsule — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Tafamidis Meglumine Capsule? options further down this page.
Why is Tafamidis Meglumine Capsule in shortage?
Pfizer has reported to the FDA that they are permanently stopping production of Vyndaqel 20 mg soft gelatin capsules, which come in a blister card of 120 capsules total (NDC 0069-8730-30). According to their report, they plan to sell through whatever supply is left and then fully stop sales in December 2025.
It's worth knowing that Pfizer did not give a specific public reason for why they made this decision — just that this particular product is being discontinued. This report covers only this specific Pfizer product and package size, so it doesn't necessarily mean tafamidis meglumine 20 mg capsules are gone from the market entirely, as other manufacturers may be listed separately on the shortage page.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Tafamidis Meglumine Capsule, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Tafamidis Meglumine Capsule?
Tafamidis meglumine (Vyndaqel) 20 mg capsules are currently on the FDA drug-shortage list, so I want to walk you through what this means for you.
The affected product is the 20 mg soft gelatin capsule (120-capsule blister card). Right now there is no available source reported for this strength, and no other strength is listed as still in stock. This is the medicine you take, so I understand this news may feel unsettling.
Here is the reason behind it: the manufacturer, Pfizer, has reported this product as to be discontinued, with manufacturing ending once current supply is exhausted and a stop-sale planned for December 2025. Because this is a discontinuation rather than a temporary delay, the supply problem may be permanent. There is no recovery date to expect.
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers, since national data may not match local stock.
- Because this product is being discontinued, talk with your prescriber soon about your next steps — they can discuss a clinician-chosen option that fits you.
Pfizer's contact number is listed on this page for reference, though your pharmacy usually handles those calls. This is general information and not individualized medical advice.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Vyndamax 61 mg | Pfizer | 1 capsule | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Tafamidis Meglumine Capsule — that fall in the same broad treatment class (protein stabilizers) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other cardiovascular shortages
Tafamidis Meglumine Capsule shortage FAQs
Is Tafamidis Meglumine Capsule in shortage?
Which products are affected?
When will Tafamidis Meglumine Capsule be available again?
What should I do if I take Tafamidis Meglumine Capsule?
Still have a question about the Tafamidis Meglumine Capsule shortage?
Ask a pharmacist about this shortage →View Tafamidis Meglumine Capsule on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.